Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP in Mallorca, Spain. It compares selected European care models rather than claiming an independent ranking of luxury centers. The UK and Switzerland are included geographically, with their own access arrangements to verify. A service’s presence in this guide does not mean it accepts every international inquiry or offers the same residential package. [1] [2]

Drug addiction covers different patterns and clinical needs. An assessment should identify prescribed and nonprescribed substances, alcohol, the pattern of use, physical and psychiatric symptoms, and previous care. It should also consider the person’s circumstances and capacity to engage with treatment. The NHS describes a range of care options selected according to the drugs involved and individual needs, rather than one treatment format for everyone. [3]

A center should be able to distinguish stabilization from ongoing treatment. If there is an acute medical or psychiatric problem, the appropriate initial service may be a hospital rather than a residence. Severe chest pain, seizures, breathing difficulty, major confusion, or an immediate psychiatric crisis require urgent medical attention. They should not wait while flights or private accommodation are arranged. [4] [5]

Be accurate about all substances, including medications taken as prescribed. The assessment should not be shaped around what you think a provider is willing to accept. If another service is needed first, ask who arranges it, what information is transferred, and who decides when a later residential stay is appropriate. COGNIFUL explicitly recognizes that withdrawal or acute needs may exceed the residential setting. [6]

Opioid treatment needs a medication discussion

Evidence-based medication is central to an opioid use disorder discussion. The CDC recommends offering or arranging medication treatment and advises against detoxification alone without it because of the increased risks of return to use and overdose. In a European search, use this clinical evidence to ask about the actual local pathway; it does not establish any particular country’s prescribing or access rules. [7]

If a medication service is already helping, ask whether moving to a different country or care setting would interrupt it. The prospective provider should explain what it can deliver and what requires coordination with another professional. Do not treat a general commitment to abstinence as a reason to discontinue appropriate medical treatment without the prescriber’s involvement.

Stimulant care should specify behavioral methods

The ASAM/AAAP guideline identifies contingency management as a primary component of stimulant use disorder treatment, with other psychosocial work. This is a structured intervention that reinforces agreed treatment behaviors. Ask whether it is actually available, how it is delivered, and how it relates to other approaches such as cognitive behavioral therapy. A website’s broad reference to individualized care is not the same as a method-specific answer. [4]

For cocaine or other stimulant use, ask how the team assesses psychiatric symptoms and physical complications. Sleep disturbance, mood changes, and other needs may continue beyond the acute period. The care plan should explain review and escalation, not assume that a short interval described as detox completes the clinical work. [4]

Prescription dependence requires careful interpretation

Physical dependence on a benzodiazepine can arise during prescribed use. Assessment should distinguish that from other patterns of problematic use and consider the condition the medication treats. The FDA warns against abrupt discontinuation or rapid reduction because of serious withdrawal risk. The relevant prescriber should guide changes; a travel date is not a clinical taper plan. [5]

Ask how treatment for sleep, anxiety, or another original concern will continue if medication is reviewed. A good proposal joins these questions together rather than treating medication reduction as the only outcome that matters. It should also explain who takes responsibility if the planned stay ends before a longer medical process does.

Cannabis treatment should address function and control

Cannabis use disorder can involve difficulty controlling use, unsuccessful attempts to reduce it, craving, and effects on responsibilities or relationships. Those features need assessment in context. Legal availability or the way a product is marketed does not determine whether the person needs help. [8]

WHO guidance identifies several psychological approaches that may be offered for cannabis dependence, including cognitive behavioral, motivational enhancement, and family work, while describing the recommendation as conditional with low-quality evidence. Ask how the proposed method fits the person and how goals are reviewed. Do not read this as a guarantee or a claim that every cannabis presentation requires residential treatment. [9]

These examples should not be compared by room category alone. A hospital’s published detox service does not prove a private residence has the same capacity. A community service may support ongoing treatment close to home without providing accommodation. Confirm exactly which intervention would be delivered, where, by whom, and through which access route.

International eligibility is a separate question from clinical suitability. An appropriate specialist service may have a local remit. A private program may accept international inquiries but determine that another setting is clinically necessary. Paying privately does not remove either boundary. Establish both before treating a provider as a realistic option.

Three different questions behind the same search term

Consider a person whose concern is a prescribed sedative taken over a long period. The first question may be how to assess dependence, review the ongoing indication, and coordinate a medically supervised change if appropriate. Asking only for a drug rehab bed could obscure that clinical history. The receiving service needs to understand what the person takes, why it was prescribed, and who has been managing it. The appropriate pathway follows that information rather than a broad marketing category. [5]

Someone seeking help with cocaine may need a different conversation about structured behavioral treatment, recurring situations, psychiatric symptoms, and whether the home environment supports engagement. A program should explain the proposed method and the reason for its intensity. The existence of a detox service is not enough to demonstrate the later stimulant treatment work. These are assessment questions, not a recommendation that every cocaine presentation belongs in the same setting. [4]

A person already receiving medication for opioid use disorder needs clarity about continuity before changing countries or providers. The important question is whether the receiving pathway preserves appropriate medical treatment and coordinates the next stage. An attractive residential offer is incomplete if it does not explain that responsibility. The CDC’s medication recommendation makes this a substantive clinical issue rather than a matter of personal preference about amenities. [7]

Ask why time away is being recommended. A residential setting may provide structure when clinically appropriate, but the recommendation should account for symptoms, engagement, support, and the home environment. If outpatient care can meet the need, a provider should be able to discuss that alternative without presenting it as a lesser commitment. [3]

Request a schedule that separates individual clinical treatment, medical review, shared activities, and other services. It should show how the components address the identified problems. A long therapy list is less useful if it does not establish which sessions the person will receive. Likewise, a small client number is not evidence of a particular clinical dose.

Ask who integrates addiction and mental health care. If different professionals contribute, clarify how they exchange information with consent and make decisions. Symptoms should not be pushed between teams without a shared understanding of responsibility. COGNIFUL describes consideration of co-occurring needs, but the exact services and professionals remain part of individual assessment. [13] [14]

Find out how the plan changes when new information emerges. What happens if a medication issue is more complex than expected? What if psychiatric symptoms require another setting? What would lead the team to recommend a different duration? These questions help separate a genuinely individualized clinical process from a fixed package with personalized language.

Progress reviews should involve the patient. Ask what goals are agreed, which measures are relevant, and how the person can discuss what is or is not helping. An outcome claim is difficult to interpret without a definition and follow-up method. More useful commitments concern what the team will assess, deliver, and review.

COGNIFUL is part of THE BALANCE GROUP and operates its residence in Mallorca, Spain. The published addiction pathways include alcohol, cocaine, prescription drugs, and cannabis. They do not establish a specialist program for every substance or acute presentation. Admission requires clinical suitability and availability, and another medical or psychiatric service may be needed before the residence is appropriate. [1] [6]

Both program tiers have a maximum of four clients at any time, with a private suite for each client. Clinical and bodywork sessions are individual. Shared elements include the residence, chef, personal manager, other holistic sessions, excursions, and activities. The model offers a small shared setting; it is not an exclusive-property arrangement. Capacity alone cannot establish staffing ratios, physician availability, or comparative effectiveness. [2]

COGNIFUL Premier and Premier Plus both include assessment, an individual plan, and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up beyond planning is agreed individually. Stays are typically described as four to twelve weeks, with personal review rather than a fixed drug-treatment timetable. [15] [16] View program fees

For a European client, ask for a proposal that specifies the relevant substances, methods, professionals, and review process. A clinician listed on THE BALANCE GROUP’s shared team is not automatically involved in every admission. Similarly, an intervention recommended by an external guideline is not a confirmed COGNIFUL service unless it appears in the agreed plan. These distinctions are useful when comparing clinical content across programs. [14] [17]

The program is self-pay and does not directly bill insurers. Request the full written fee proposal, including duration assumptions, inclusions, and exclusions. Discuss external medical services and follow-up in the country where you live. COGNIFUL’s continuing-care work should become an actual arrangement with receiving professionals, not an assumption that remote treatment or prescribing is available across every European jurisdiction. [15] [16] [18]

International care may involve a referring clinician, a medical stabilization service, a residence, and a home follow-up team. Name the person responsible at each transition. Agree which records are required, how consent is handled, and who confirms readiness for the next setting. A transfer is not complete merely because travel has been arranged.

Language should be checked for the full clinical pathway. Confirm assessment, therapy, consent discussions, family meetings, and discharge information in a language the patient can use comfortably. Where the receiving team uses another language, agree how essential recommendations will be communicated accurately. Being able to make an admission call does not establish the same access throughout treatment.

Medication arrangements may require particular coordination when care crosses a border. Ask the responsible professionals about prescribing, dispensing, monitoring, and relevant travel requirements for the actual medication and route. Do not assume that shared geography creates a single European medical system or that an overseas recommendation guarantees local continuation.

Work and family commitments also need realistic planning. Ask how the proposed schedule affects availability for outside responsibilities and what practical support can be arranged. If relatives participate in treatment, agree the purpose and consent boundaries. Their logistical help should not become a substitute for professional follow-up.

Before discharge, translate continuing care into appointments, contacts, and responsibilities. What happens if symptoms worsen? Who responds if substance use returns? Which professional reviews medication? A useful plan makes the next step accessible, including reassessment where necessary, instead of treating the residential stay as a guarantee against future difficulty.

Ask each realistic option for a written explanation of the proposed duration and services. If one provider suggests a short intensive episode and another a longer residence, ask which needs drive that difference. A fee comparison is meaningful only when you understand what clinical work is included, which professionals are available, and what the next stage will require. Avoid assuming that more weeks always mean more appropriate care.

Clarify how external assessments, additional medical services, and follow-up are handled financially. Do not assume they are all included or all excluded. For international treatment, add known travel and practical arrangements to the comparison while keeping clinical recommendations separate from convenience. Any anticipated reimbursement should be checked through the actual payer rather than inferred from a provider’s willingness to supply documents.

Privacy is another element to define precisely. Ask who receives clinical information, what an employer or relative arranging payment can see, and which spaces or activities are shared. A private suite is a concrete accommodation feature; it is not a guarantee that every part of the experience is solitary or anonymous. Understanding the arrangement helps the person choose a setting in which they can participate comfortably.

Finally, ask what information is still missing before a final recommendation can be made. A careful admission process can acknowledge uncertainty and request records or an assessment. That is part of choosing a suitable treatment pathway, especially when several substances and more than one country’s clinicians are involved.

Are all European addiction centers open to international clients?

No. Eligibility, referral, age, catchment, and language requirements differ. For example, the Zurich service describes adults aged 18–65 and preferably canton residents. Confirm the actual route before making a service part of an international plan. [12]

Does a detox service cover all later treatment?

No. Stabilization and ongoing addiction treatment are distinct responsibilities. For opioid use disorder, medication treatment is an important part of the pathway, and detoxification alone without it is not recommended by the CDC. [7]

Can COGNIFUL treat every drug problem?

Its published addiction pathways have a defined scope, and admission depends on assessment. Ask about the specific substances, medical needs, and mental health symptoms involved. Another service may need to lead care first. [1] [6]

What should I do before booking Mallorca travel?

Obtain clinical acceptance, a written treatment and fee proposal, and an agreed plan for any prior care and later follow-up. Where another clinician is involved, arrange a consent-based handoff rather than carrying uncoordinated recommendations between services. [18] [19]

1. Addiction treatment at COGNIFUL — COGNIFUL
2. Life at COGNIFUL in Mallorca — COGNIFUL
3. Drug addiction: getting help — NHS
4. ASAM/AAAP clinical practice guideline on the management of stimulant use disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry
5. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class — US Food and Drug Administration
6. Clinical scope, suitability and care coordination — COGNIFUL
7. Opioid use disorder: treating — Centers for Disease Control and Prevention
8. Understanding your risk for cannabis use disorder — Centers for Disease Control and Prevention
9. Psychosocial interventions for cannabis dependence — World Health Organization
10. Treatment options at Jellinek — Jellinek
11. Priory Hospital Roehampton, London — Priory
12. Addiction disorders and dual diagnoses — Psychiatric University Hospital Zurich
13. Co-occurring mental health and addiction needs — COGNIFUL
14. How residential treatment works at COGNIFUL — COGNIFUL
15. COGNIFUL programs, fees and admissions — COGNIFUL
16. Reintegration and continuing care — COGNIFUL
17. Clinical team and care coordination — COGNIFUL
18. Professional referrals — COGNIFUL
19. Considering residential treatment in Mallorca: what to check before traveling — COGNIFUL

Source information checked October 18, 2026. Confirm current services, eligibility, fees, and availability directly with each provider.